CR20230473A - Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. - Google Patents

Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.

Info

Publication number
CR20230473A
CR20230473A CR20230473A CR20230473A CR20230473A CR 20230473 A CR20230473 A CR 20230473A CR 20230473 A CR20230473 A CR 20230473A CR 20230473 A CR20230473 A CR 20230473A CR 20230473 A CR20230473 A CR 20230473A
Authority
CR
Costa Rica
Prior art keywords
methods
binding fragment
subcutaneous administration
cancer
antibodies
Prior art date
Application number
CR20230473A
Other languages
English (en)
Spanish (es)
Inventor
Miranda Silva Carolina De
Gheyas Yogita Krishnamachari
Mallika Lala
Ferdous Gheyas
Lokesh Jain
Elliot Keith Chartash
Venkata Naga Ratna Pavan Kumar Vaddady
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of CR20230473A publication Critical patent/CR20230473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20230473A 2021-04-08 2022-04-04 Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. CR20230473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172299P 2021-04-08 2021-04-08
PCT/US2022/023250 WO2022216580A1 (en) 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (1)

Publication Number Publication Date
CR20230473A true CR20230473A (es) 2023-11-30

Family

ID=83546458

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230473A CR20230473A (es) 2021-04-08 2022-04-04 Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.

Country Status (21)

Country Link
US (1) US20250074983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320163A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024513247A (cg-RX-API-DMAC7.html)
KR (1) KR20230170029A (cg-RX-API-DMAC7.html)
CN (1) CN117279952A (cg-RX-API-DMAC7.html)
AR (1) AR125296A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022254960A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020867A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214617A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002976A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023013273A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230473A (cg-RX-API-DMAC7.html)
DO (2) DOP2023000216A (cg-RX-API-DMAC7.html)
EC (1) ECSP23076276A (cg-RX-API-DMAC7.html)
GE (1) GEAP202416385A (cg-RX-API-DMAC7.html)
IL (1) IL307430A (cg-RX-API-DMAC7.html)
JO (1) JOP20230243A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011857A (cg-RX-API-DMAC7.html)
PE (1) PE20240051A1 (cg-RX-API-DMAC7.html)
TW (1) TW202305009A (cg-RX-API-DMAC7.html)
WO (1) WO2022216580A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂
WO2026124472A1 (zh) * 2024-12-10 2026-06-18 四川科伦博泰生物医药股份有限公司 治疗组合及其用途和治疗方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634484A4 (en) * 2017-06-05 2022-01-12 The Council of the Queensland Institute of Medical Research A COMBINATION OF OR A BI-SPECIFIC BINDING MOLECULE TO AN IMMUNOCONTROL MOLECULE ANTAGONIST AND A RANK-L (NF-κB-LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210380694A1 (en) * 2018-11-07 2021-12-09 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN112203642B (zh) * 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物

Also Published As

Publication number Publication date
DOP2026000117A (es) 2026-07-31
ECSP23076276A (es) 2023-11-30
EP4320163A1 (en) 2024-02-14
TW202305009A (zh) 2023-02-01
CA3214617A1 (en) 2022-10-13
WO2022216580A1 (en) 2022-10-13
MX2023011857A (es) 2023-10-19
CO2023013273A2 (es) 2023-10-30
GEAP202416385A (en) 2024-02-26
IL307430A (en) 2023-12-01
JP2024513247A (ja) 2024-03-22
AU2022254960A1 (en) 2023-11-23
EP4320163A4 (en) 2025-03-05
JOP20230243A1 (ar) 2023-10-08
CN117279952A (zh) 2023-12-22
CL2023002976A1 (es) 2024-06-28
PE20240051A1 (es) 2024-01-09
US20250074983A1 (en) 2025-03-06
KR20230170029A (ko) 2023-12-18
AU2022254960A9 (en) 2023-11-30
DOP2023000216A (es) 2023-11-30
BR112023020867A2 (pt) 2023-12-12
AR125296A1 (es) 2023-07-05

Similar Documents

Publication Publication Date Title
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
EA201992590A1 (ru) Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения
MX2023004399A (es) Tratamiento de combinacion.
MX2025004328A (es) Composiciones y metodos para el tratamiento del cancer con administracion subcutanea de anticuerpos anti-pd1
RU2011144312A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА
GEAP202416385A (en) Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
CL2025002617A1 (es) Conjugados anticuerpo-fármaco administrados por vía subcutánea para el uso en el tratamiento del cáncer
MX2025008525A (es) Métodos y composiciones para la terapia combinada
BR112023026111A2 (pt) Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
DOP2025000008A (es) Composición farmacéutica de anticuerpo anti-cd20 y uso de la misma
Stakiw et al. A Phase II, Open-label study of an accelerated infusion rate of daratumumab in patients with relapsed and refractory multiple myeloma
AR130745A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
MX2022013663A (es) Anticuerpo biespecifico o fragmento de union a antigeno del mismo, y metodo de preparacion del mismo.
GB2599546A (en) IL-ER#/IL-8R Bispecific binding agents for inhibiting cancer cell migration
AR134765A1 (es) Usos de inmunoconjugados il-2 atenuados
MX2025010217A (es) Anticuerpos multiespecificos anti-cd3 y metodos de uso
EA201892343A1 (ru) Новые в7-н3 связывающие молекулы, содержащие их конъюгаты антитело-лекарственное средство и способы их применения
MX2025005847A (es) Anticuerpos anti-cd137 y metodos de uso
AR133888A1 (es) ANTICUERPOS IL-5R-a PARA EL TRATAMIENTO DE LA GRANULOMATOSIS EOSINOFÍLICA CON POLIANGITIS
MX2025009423A (es) Anticuerpo anti cumulo de diferenciacion 25 (cd25) y conjugado anticuerpo anti cumulo de diferenciacion 25 (cd25)-farmaco
MX2024010446A (es) Metodos para administrar anticuerpos biespecificos mimeticos del factor de coagulacion viii (fviii) una vez al mes.
AR124527A1 (es) Métodos de tratamiento de tumores
EA202091738A1 (ru) Способы лечения рака антителами-антагонистами к pd-1